Michael A. Gorin, MD, a urologist with Urology Associates of Cumberland, Maryland, explains the benefits of transperineal prostate biopsy compared to the transrectal approach for prostate cancer patients. First, he discusses the complications of transrectal biopsy, specifically infection risk, and demonstrates how the transperineal approach can decrease this risk without contributing to antibiotic resistance. He then explains how transperineal biopsy aids in improved detection and cancer upgrading. Dr. Gorin goes on to review transperineal biopsy methods, including the use of the Precisionpoint Transperineal access system. Finally, he summarizes block techniques and biopsy templates for freehand transperineal prostate biopsy under local anesthesia in the outpatient setting.Read More
Michael A. Gorin, MD
Dr. Gorin is a fellowship-trained minimally invasive urologist based in Western Maryland. He is also the Director of Medical Affairs for Perineologic, maker of the PrecisionPoint Transperineal Access System. Dr. Gorin’s clinical practice focuses on adult general urology with a special interest in caring for patients with kidney stones, benign prostatic hyperplasia (BPH), and prostate cancer. Dr. Gorin is considered as a thought leader in the field for his research on molecular imaging of genitourinary cancers. He is also widely known for his work developing novel methods for performing MRI-guided transperineal prostate biopsy and focal cryoablation ablation of the prostate. Dr. Gorin has published over 225 articles in peer-reviewed journals and has contributed to multiple medical textbooks, including chapters in Campbell-Walsh-Wein Urology, The 5-Minute Urology Consult, and Gray’s Anatomy. Dr. Gorin also serves on the editorial boards of several journals including UROLOGY (the Gold Journal), British Journal of Urology International, and World Journal of Urology and has received numerous honors and awards for his scholarly work. Dr. Gorin attended college at the University of Michigan where he earned a Bachelor of Science in Cellular and Molecular Biology. He then went on to attend medical school at the University of Miami Leonard M. Miller School of Medicine where he graduated as an inductee to the Alpha Omega Alpha Honor Medical Society. Following medical school, Dr. Gorin completed a general surgery internship, urology residency, and a fellowship in endoscopic and minimally invasive urology at Johns Hopkins University School of Medicine. Dr. Gorin earned a Bachelor of Science in Cellular and Molecular Biology from the University of Michigan in Ann Arbor. He then went on to attend medical school at the University of Miami Leonard M. Miller School of Medicine, where he graduated as an inductee to the Alpha Omega Alpha Honor Medical Society. Following medical school, Dr. Gorin completed a general surgery internship, urology residency, and fellowship in endoscopic and minimally-invasive urology at Johns Hopkins University School of Medicine.Disclosures:
Dr. Gorin is Director of Medical Affairs for Perineologic.
Articles by Michael A. Gorin, MD
Posted by Michael A. Gorin, MD | Dec 2020
Michael A. Gorin, MD, discusses biomarkers for diagnosing prostate cancer, including PSA, mpMRI, and serum and urine tests. He gives an overview of the history of prostate specific antigen (PSA), emphasizing that PSA screening is beneficial even as he acknowledges that PSA’s high sensitivity and low specificity result in many unnecessary biopsies. There are now many serum and urine biomarker tests that can help provide more specificity, including 4KScore, Prostate Health Index, SelectMDx, and ExoDx Prostate IntelliScore (EPI), all of which are endorsed by the NCCN Guidelines. Dr. Gorin notes that, when price is considered, SelectMDx and EPI outperform the other tests. Dr. Gorin concludes the presentation by discussing how multiparametric MRI should be used in prostate cancer diagnosis, noting that while there is little official guidance on this yet, he uses it in his own practice if a patient has a PSA ≥3 and receives an abnormal result from a serum or urine biomarker test.Read More
Posted by Michael A. Gorin, MD | Jun 2020
Michael A. Gorin, MD, a urologist at Urology Associates of Cumberland, Maryland, and Director of Medical Affairs for Perineologic, discusses the benefits of transperineal prostate biopsy over transrectal biopsy. He notes that transrectal prostate biopsy leads to infections in 5-7% of patients, and argues that transperineal biopsy is the best alternative for avoiding infection. Dr. Gorin acknowledges that the use of a grid-stepper unit for performing transperineal biopsy can be uncomfortable for patients, but suggests that new technology like the PrecisionPoint™ Transperineal Access System solves many of these issues. The presentation is followed by a Q&A in which Dr. Gorin discusses the importance of new coding for transperineal biopsy and the potential of variable length needles.Read More
Join the GRU Community- Why Join? -
CARDEN JENNINGS PUBLISHING CO., LTD.
- PDF Embedder Test Jan 2022
- Genetic Testing and Prostate Cancer – Welcome Jan 2022
- Current Status of PSMA Diagnostics Aug 2021
- Genetic Testing and Prostate Cancer Aug 2021
- What’s New in Active Surveillance for Prostate Cancer in 2021 Aug 2021
Exercise & Wellness
Fred Bartlit, Esq.
Mark A. Moyad, MD, MPH
University of Michigan
Ann Arbor, Michigan